HEALTH INEQUITY: Red Cross Children’s Hospital Doctor Using Donated ‘Miracle’ Cystic Fibrosis Drug to Save Lives

Why It Matters

Limited access to Trikafta underscores systemic barriers for rare‑disease patients in low‑ and middle‑income markets, threatening lives and widening health disparities.

Key Takeaways

• Trikafta costs ~US$300k annually, unaffordable for most South Africans.
• Only ~200 of 400‑450 CF patients receive Trikafta in SA.
• Doctors use donated surplus and reduced dosing to stretch supply.
• Lack of SAHPRA registration forces Section 21 approvals every six months.
• Equity Pharma deal limits Trikafta to top‑tier medical aid holders.

Pulse Analysis

Trikafta’s 2019 launch transformed cystic fibrosis care, delivering unprecedented improvements in lung function and life expectancy. Yet its US list price—over $300,000 per patient per year—places it beyond the reach of most health systems, especially in emerging economies. In South Africa, the drug remains unregistered with the Health Products Regulatory Authority, meaning public hospitals cannot procure it through standard channels. This regulatory gap forces clinicians to seek Section 21 exemptions, a cumbersome process that must be renewed every six months, further complicating long‑term treatment planning.

Faced with these obstacles, Red Cross Children’s Hospital has pioneered a pragmatic drug‑sharing model. Physicians identify private‑sector patients who experience side effects or can tolerate reduced dosing, then collect surplus tablets for redistribution to public‑sector children. By pairing Trikafta with clarithromycin, clinicians can halve the dosing frequency, extending limited supplies to more patients. The approach has saved lives—Jaylin Leitjies, once on the brink of death, now thrives without hospital admissions—but it remains fragile, dependent on voluntary donations and unable to meet the full demand of roughly 400‑450 South African CF patients.

The broader policy landscape points to a need for systemic change. Advocates urge the inclusion of Trikafta on the national Essential Medicines List and call for Vertex to negotiate a public‑sector price that reflects local purchasing power. Without SAHPRA registration, procurement through provincial Pharmacy and Therapeutic Committees remains stalled, perpetuating inequity. Sustainable access will likely require a combination of compulsory licensing, price‑setting mechanisms, and public‑private partnerships that prioritize rare‑disease treatments irrespective of patients' socioeconomic status.